| Identification | Back Directory | [Name]
NJK14047 | [CAS]
1800576-41-3 | [Synonyms]
NJK14047
[1,1'-Biphenyl]-3-carboxamide, N-cyclopropyl-4'-[4-(2,3-dihydroxypropoxy)benzoyl]-6-methyl- | [Molecular Formula]
C27H27NO5 | [MOL File]
1800576-41-3.mol | [Molecular Weight]
445.51 |
| Hazard Information | Back Directory | [Uses]
NJK14047 inhibits p38 MAPK and the differentation of naive T-cells to Th1 and Th17 cells. NJK14047 ameliorates the collage-induced rheumatoid arthritis and Imiquimod (HY-B0180)-induced psoriasis in mice[1]. | [in vivo]
NJK14047 (2.5 mg/kg, i.p. for 7-21 days) ameliorates the collage-induced rehumatoid arthritis (CIA) in DBA-1J mice and Imiquimod (HY-B0180)-induced psoriasis (IIP) in BALB/c mice, suppresses the cytokines expressions of Th1, Th2, Th17 and Treg[1]. | Animal Model: | collage-induced rehumatoid arthritis in DBA-1J mice and imiquimod-induced psoriasis in BALB/c mice[1] | | Dosage: | 2.5 mg/kg | | Administration: | i.p. for 7 days for IIP-administrated BALB/c mice, i.p. for 21 days for CIA-administrated CBA-1J mice | | Result: | Ameliorated the collage-induced arthritis and CIA caused cartilage damage, inflammation, pannus formation, bone corrosion, and synovial hyperplasia.
Ameliorated the imiquimod induced psoriasis and IIP caused keratinocyte proliferation. |
| [References]
[1] Lee JH, et al., NJK14047 inhibition of p38 MAPK ameliorates inflammatory immune diseases by suppressing T cell differentiation. Int Immunopharmacol. 2024 Mar 30;130:111800. DOI:10.1016/j.intimp.2024.111800 |
|
|